The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Abstract
The induction of anti-influenza cytotoxic T lymphocytes (CTL) in vivo by immunizing mice with liposomes containing messenger RNA (mRNA) encoding the influenza virus nucleoprotein (NP) is described. NP mRNA, obtained by in vitro transcription, was encapsulated into simple cholesterol/phosphatidylcholine/phosphatidylserine liposomes by the detergent removal technique. The dependence of the route of mRNA-liposomes delivery on CTL induction was studied. The CTL induced were identical to those obtained in vivo with infectious virus in terms of specificity, lysing both peptide-sensitized and virus-infected targets. Furthermore, with the same mRNA-liposome preparation, virus-specific CTL responses could be also elicited in mice of three different haplotypes each of them known to present a distinct NP peptide in an MHC-restricted fashion. The relevance of these results in the context of vaccine development is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence, mRNA vaccines have been formulated with synthetic delivery vehicles such as liposomes (16) and cationic polymers (17) to increase potency.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [16]
In the citing paper
“It was not until 1993 that mRNA was used as a vaccine for the first time to elicit a specific immune response against the encoded pathogenic antigen in a preclinical setting using lipid-based delivery.22”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [22]
In the citing paper
“The first mRNA vaccine was made of liposomes and mRNA encoding an influenza virus nucleoprotein184.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [184]
In the citing paper
“This vaccine, designed in 1993, was able to induce virus-specific cytotoxic T cell responses in mice184.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [184]
In the citing paper
“Lipid nanoparticle–mRNA vaccines are also being investigated as influenza vaccines29,41,156,157,159,184,189–191, with some formulations in clinical trials (Table 1).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [184]
In the citing paper
“As pioneers, Martinon et al. showed that liposomes containing mRNA encoding the influenza virus nucleoprotein elicited virus-specific cytotoxic T lymphocytes (CTLs) [3].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [3]
In the citing paper
“encapsulation of RNA in lipid carriers 72 , and their utility in vaccination 73 , was demonstrated.”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [73]
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
Deres, K., Schild, H., Wiesmüller, K., Jung, G., & Rammensee, H. (1989) · Nature · doi:10.1038/342561a0 · Cited by 632
Morrison, L. A., Lukacher, A. E., Braciale, V. L., Fan, D. P., & Braciale, T. J. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.4.903 · Cited by 507
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
Takahashi, H., Takeshfta, T., Morein, B., Putney, S. D., Germain, R. N., & Berzofsky, J. A. (1990) · Nature · doi:10.1038/344873a0 · Cited by 473
A molecular model of MHC class-I-restricted antigen processing
Monaco, J. J. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90122-n · Cited by 433
Kast, W. M., Roux, L., Curren, J., Blom, H., Voordouw, A. C., Meloen, R. H., Kolakofsky, D., & Melief, C. J. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2283 · Cited by 326
Peptide-induced antiviral protection by cytotoxic T cells.
Schulz, M., Zinkernagel, R. M., & Hengartner, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.991 · Cited by 239
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.
Aichele, P., Hengartner, H., Zinkernagel, R. M., & Schulz, M. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1815 · Cited by 198
Townsend, A., & Skehel, J. J. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.160.2.552 · Cited by 182
Cited by
Sorted by citations
Items 101–200 of 472
New Kids on the Block: RNA-Based Influenza Virus Vaccines
Scorza, F. B., & Pardi, N. (2018) · Vaccines · doi:10.3390/vaccines6020020 · Cited by 91
Golombek, S., Pilz, M., Steinle, H., Kochba, E., Levin, Y., Lunter, D., Schlensak, C., Wendel, H. P., & Avci-Adali, M. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.005 · Cited by 88
Bouazzaoui, A., Abdellatif, A. A. H., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020140 · Cited by 92
Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
Pascolo, S. (2021) · Viruses · doi:10.3390/v13020270 · Cited by 87
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 94
Recent progress in mRNA cancer vaccines
Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 91
Fiedler, K., Lazzaro, S., Lutz, J., Rauch, S., & Heidenreich, R. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_5 · Cited by 88
A new developing class of gene delivery: messenger RNA-based therapeutics
Zhao, M., Ahern, J. O., Lyu, J., Pierucci, L., Zhou, D., & Wang, W. (2017) · Biomaterials Science · doi:10.1039/c7bm00712d · Cited by 95
Characterization of the ribonuclease activity on the skin surface
Probst, J., Brechtel, S., Scheel, B., Hoerr, I., Jung, G., Rammensee, H.-G., & Pascolo, S. (2006) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-4-4 · Cited by 84
Influenza Vaccines: Successes and Continuing Challenges
Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab269 · Cited by 83
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104
Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects
Huang, T., Peng, L., Han, Y., Wang, D., He, X., Wang, J., & Ou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922301 · Cited by 87
A novel delivery platform based on Bacteriophage MS2 virus-like particles
Fu, Y., & Li, J.-M. (2015) · Virus Research · doi:10.1016/j.virusres.2015.08.022 · Cited by 68
DNA and mRNA vaccination against allergies
Scheiblhofer, S., Thalhamer, J., & Weiss, R. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.12964 · Cited by 81
Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles
Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s39810 · Cited by 79
HIV mRNA Vaccines—Progress and Future Paths
Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 84
Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
Duan, L.-J., Wang, Q., Zhang, C., Yang, D.-X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923647 · Cited by 83
Viral and Synthetic RNA Vector Technologies and Applications
Schott, J. W., Morgan, M., Galla, M., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.143 · Cited by 76
Xue, T., Stavropoulos, E., Yang, M., Ragno, S., Vordermeier, M., Chambers, M., Hewinson, G., Lowrie, D. B., Colston, M. J., & Tascon, R. E. (2004) · Infection and Immunity · doi:10.1128/iai.72.11.6324-6329.2004 · Cited by 73
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
Plasmid DNA expression systems for the purpose of immunization
Davis, H. L. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80041-9 · Cited by 72
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Şahin, U. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1288 · Cited by 74
mRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 74
Messenger RNA (mRNA) nanoparticle tumour vaccination
Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70
Liu, M. A. (1998) · Nature Medicine · doi:10.1038/nm0598supp-515 · Cited by 70
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
mRNA vaccines: The future of prevention of viral infections?
Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 75
Perspectives on RNA Vaccine Candidates for COVID-19
Borah, P., Deb, P. K., Al‐Shar’i, N. A., Dahabiyeh, L. A., Venugopala, K. N., Singh, V., Shinu, P., Hussain, S., Deka, S., Chandrasekaran, B., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635245 · Cited by 67
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response
Crews, D. W., Dombroski, J. A., & King, M. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626463 · Cited by 65
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 68
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 64
Therapeutic mRNA delivery to leukocytes
Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 64
mRNA-Loaded Lipid Nanoparticles Targeting Immune Cells in the Spleen for Use as Cancer Vaccines
Shimosakai, R., Khalil, I. A., Kimura, S., & Harashima, H. (2022) · Pharmaceuticals · doi:10.3390/ph15081017 · Cited by 63
Breaking the mold with RNA—a “RNAissance” of life science
Jones, C. H., Androsavich, J. R., So, N., Jenkins, M. P., MacCormack, D., Prigodich, A. E., Welch, V., True, J. M., & Dolsten, M. (2024) · npj Genomic Medicine · doi:10.1038/s41525-023-00387-4 · Cited by 70
Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22661 · Cited by 59
Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 64
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
Cu, Y., Broderick, K. E., Banerjee, K., Hickman, J., Otten, G. R., Barnett, S. W., Kichaev, G., Sardesai, N. Y., Ulmer, J. B., & Geall, A. J. (2013) · Vaccines · doi:10.3390/vaccines1030367 · Cited by 58
Messenger RNA-Based Vaccines Against Infectious Diseases
Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96
New Technologies for Influenza Vaccines
Rockman, S. P., Laurie, K., Parkes, S., Wheatley, A. K., & Barr, I. (2020) · Microorganisms · doi:10.3390/microorganisms8111745 · Cited by 58
Use of Plasmid DNA for Direct Gene Transfer and Immunization
Davis, H. L., Michel, M., & Whalen, R. G. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44728.x · Cited by 56
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
Tombácz, I., Weissman, D., & Pardi, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 55
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57
mRNA vaccines: a new era in vaccine development
Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 51
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
Messenger RNA‐based vaccines: progress, challenges, applications
Kramps, T., & Probst, J. (2013) · WIREs RNA · doi:10.1002/wrna.1189 · Cited by 50
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Current Vaccine Platforms in Enhancing T-Cell Response
Ura, T., Takeuchi, M., Kawagoe, T., Mizuki, N., Okuda, K., & Shimada, M. (2022) · Vaccines · doi:10.3390/vaccines10081367 · Cited by 56
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 51
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51
Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression
Kim, H., Park, Y., & Lee, J. B. (2015) · Scientific Reports · doi:10.1038/srep12737 · Cited by 50
Modified mRNA as a Therapeutic Tool for the Heart
Kaur, K., & Zangi, L. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07051-4 · Cited by 50
Nano-Microparticle Platforms in Developing Next-Generation Vaccines
Cappellano, G., Abreu, H., Casale, C., Dianzani, U., & Chiocchetti, A. (2021) · Vaccines · doi:10.3390/vaccines9060606 · Cited by 50
mRNA therapy at the convergence of genetics and nanomedicine
Conde, J., Langer, R., & Rueff, J. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01347-w · Cited by 49
Vaccines against influenza A viruses in poultry and swine: Status and future developments
Rahn, J., Hoffmann, D., Harder, T., & Beer, M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.052 · Cited by 51
mRNA vaccines in the context of cancer treatment: from concept to application
Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06033-6 · Cited by 59
Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19?
Li, D., Liu, C., Li, Y., Tenchov, R., Sasso, J. M., Zhang, D., Li, D., Zou, L., Wang, X., & Zhou, Q. A. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00047 · Cited by 50
Vignuzzi, M., Gerbaud, S., van der Werf, S., & Escriou, N. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-7-1737 · Cited by 47
Potential health risks of mRNA-based vaccine therapy: A hypothesis
Acevedo‐Whitehouse, K. A., & Bruno, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111015 · Cited by 56
mRNA Cancer Vaccines—Messages that Prevail
Grunwitz, C. R., & Kranz, L. M. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_509 · Cited by 47
Schirmbeck, R., & Reimann, J. (2001) · Biological Chemistry · doi:10.1515/bc.2001.068 · Cited by 46
Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action
Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 46
Synthetic mRNAs for manipulating cellular phenotypes: an overview
Quabius, E. S., & Krupp, G. (2014) · New Biotechnology · doi:10.1016/j.nbt.2014.04.008 · Cited by 47
Vaccines ‘on demand’: science fiction or a future reality
Ulmer, J. B., Mansoura, M. K., & Geall, A. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.996128 · Cited by 45
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy
García-Fernández, C., Fornaguera, C., & Borrós, S. (2020) · Cancers · doi:10.3390/cancers12061609 · Cited by 44
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
mRNA vaccination as a safe approach for specific protection from type I allergy
Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., & Thalhamer, J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.168 · Cited by 42
Abdelaziz, K., Helmy, Y. A., Yitbarek, A., Hodgins, D. C., Sharafeldin, T. A., & Selim, M. H. (2024) · Vaccines · doi:10.3390/vaccines12020134 · Cited by 47
Nucleic acids: Vaccines of the future
Waine, G. J., & McManus, D. P. (1995) · Parasitology Today · doi:10.1016/0169-4758(95)80172-3 · Cited by 42
Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Zhao, Y., Gan, L., Ke, D., Chen, Q., & Fu, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04553-1 · Cited by 45
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Wei, J., & Hui, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s341694 · Cited by 42
Yokoyama, M., Zhang, J., & Whitton, J. L. (1996) · FEMS Immunology & Medical Microbiology · doi:10.1016/0928-8244(96)00033-8 · Cited by 41
Advances in nucleic acid-based cancer vaccines
Liao, H., & Liu, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01102-w · Cited by 46
Vaccines platforms and COVID-19: what you need to know
Acosta-Coley, I., Cervantes-Ceballos, L., Benítez, L. P. T., Sierra-Marquez, L., Cabarcas-Montalvo, M., Espiñeira, M. C. G., Coronell-Rodríguez, W., & Arroyo-Salgado, B. (2022) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-022-00176-4 · Cited by 40
Bacterial delivery of functional messenger RNA to mammalian cells
Schoen, C. U., Kolb‐Mäurer, A., Geginat, G., Löffler, D., Bergmann, B., Stritzker, J., Szalay, A. A., Pilgrim, S., & Goebel, W. (2005) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00507.x · Cited by 40
The messenger's great message for vaccination
Pascolo, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1000871 · Cited by 40
The immunological potential of apoptotic debris produced by tumor cells and during HIV infection
Kornbluth, R. S. (1994) · Immunology Letters · doi:10.1016/0165-2478(94)00149-9 · Cited by 38
Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery
Khan, M. S., Appak‐Baskoy, S., Yang, C. J., Hong, J., Chae, J., Ha, H.-J., Lee, S., Tanaka, M., Choi, Y., & Choi, J. H. (2023) · Nanoscale Advances · doi:10.1039/d2na00795a · Cited by 37
Regulatory Considerations on the Development of mRNA Vaccines
Naik, R., & Peden, K. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_220 · Cited by 37
Saxena, S., Sonwane, A., Dahiya, S. S., Patel, C. L., Saini, M., Rai, A., & Gupta, P. K. (2008) · Veterinary Microbiology · doi:10.1016/j.vetmic.2008.10.030 · Cited by 37
A Short History of Vaccination
Plotkin, S. L., & Plotkin, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00001-3 · Cited by 43
Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
Provine, N. M., & Klenerman, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202250022 · Cited by 37
A new dawn for monoclonal antibodies against antimicrobial resistant bacteria
Troisi, M., Marini, E., Abbiento, V., Stazzoni, S., Andreano, E., & Rappuoli, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1080059 · Cited by 39
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 36
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Influenza Viruses: Innate Immunity and mRNA Vaccines
Lee, S., & Ryu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710647 · Cited by 36
Davis, H. L., & Whalen, R. G. (1995) · Springer eBooks · doi:10.1007/978-94-011-0547-7_18 · Cited by 35
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 38
Stimuli-responsive nanomaterials for the precision delivery of mRNA cancer vaccines
Srivastava, R. (2025) · Nano Trends · doi:10.1016/j.nwnano.2025.100147 · Cited by 36
DeWeerdt, S. (2019) · Nature · doi:10.1038/d41586-019-03068-4 · Cited by 35
Synthesis of point-modified mRNA
Hertler, J., Slama, K., Schober, B., Özrendeci, Z., Marchand, V., Motorin, Y., & Helm, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac719 · Cited by 35
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 35
Minor Intron Splicing from Basic Science to Disease
Marabti, E. E., Malek, J. A., & Younis, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116062 · Cited by 33
Metadata
- Authors
- Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P.
- Affiliations
- Inserm (FR)
- Institut Cochin (FR)
- Corresponding author
- Meulien, Pierre
- ORCID
- Martinon, Frédéric
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1993-07
- Volume
- 23
- Issue
- 7
- Pages
- 1719-1722
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2083958143
- Cited by
- 473
- References
- 28
- Citations by year
- 2026: 18 · 2025: 42 · 2024: 51 · 2023: 59 · 2022: 58 · 2021: 64 · 2020: 18 · 2019: 10 · 2018: 12 · 2017: 8 · 2016: 12 · 2015: 13 · 2014: 12 · 2013: 9 · 2012: 10
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- cytotoxic T lymphocytes, influenza virus, nucleocapsid protein, mRNA vaccines, MHC restriction, peptide presentation, vaccine development, in vitro transcription
- MeSH terms
- Animals, Antigens, Viral, Cytotoxicity, Immunologic, Immunity, Cellular, Liposomes, Mice, Inbred Strains, Nucleoproteins, Influenza A virus, RNA, Messenger, T-Lymphocytes, Cytotoxic, Vaccines, Synthetic, Viral Core Proteins, Viral Vaccines, Nucleocapsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
